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Abstract
Background: The development of new treatments against schistosomiasis is imperative but lacks commercial interest.
Drug repurposing represents a suitable strategy to identify potential treatments, which have already unblocked several
essential steps along the drug development path, hence reducing costs and timelines. Promoting this approach, the
Medicines for Malaria Venture (MMV) recently distributed a drug repurposing library of 400 advanced lead candidates
(Stasis Box).
Methods: All 400 compounds were initially tested in vitro against the larval stage of Schistosoma mansoni at 10 μM.
Hits progressed to screening on adult worms and were further characterised for IC50, cytotoxicity and selectivity. Ten
lead compounds were tested in mice harbouring a chronic S. mansoni infection.
Results: Eleven of the 37 compounds active on the larval stage were also highly active on adult worms in vitro
(IC50 = 2.0–7.5 μM). IC50 values on adult S. mansoni decreased substantially in the presence of albumin (7.5–123.5 μM).
Toxicity to L6 and MRC cells was moderate. A moderate worm burden reduction of 51.6% was observed for
MMV690534, while the other 9 compounds showed low activity. None of the in vivo results were statistically
significant (P > 0.05).
Conclusions: Phenotypic screening of advanced lead compounds is a simple and resource-low method to
identify novel anthelminthics. None of the promising hits of the Stasis Box identified in vitro against S. mansoni
yielded acceptable worm burden reductions in vivo, which might be due to the high plasma protein binding.
Since the in vitro hits interfere with different drug targets, they might provide a starting point for target based
screening and structure-activity relationship studies.
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Background
The lack of proper sanitation infrastructure worldwide
puts more than 700 million people - mostly children - at
risk of acquiring schistosomiasis [1–3]. This tropical para-
sitosis, transmitted by Schistosoma spp. trematodes, causes
a wide range of severe chronic morbidities that affect the
digestive and the urogenital system [2, 4]. Listed as a
neglected tropical disease (NTD), schistosomiasis accounts
for more than 2.6 million disability-adjusted life years
(DALYs) lost [5]. Schistosomiasis has a considerable socio-
economic impact in endemic countries, notably by redu-
cing the attendance at school or work place [6, 7]. Schisto-
somiasis is almost exclusively controlled by preventive
chemotherapy with praziquantel. Safe, affordable and an
oral treatment, praziquantel presents many advantages [8].
With the global aim to eliminate the disease as a public
health problem in the next decade, formalized by the
London Declaration on Neglected Tropical Diseases [9],
praziquantel treatment coverage will substantially increase
over the next years [3, 10]. A major concern is that, in ab-
sence of any alternative on the market or advanced candi-
dates in the drug discovery and development pipeline,
such intensified use would result in the emergence of
drug resistance [11–13]. Hence, in order to meet the
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long-term goal of elimination, new drug candidates
have to be urgently identified [14, 15].
As the return on investment for a new antischistoso-
mal treatment is expected to be very low (or inexistent),
drug repurposing is a cost-effective solution to expand
the pool of therapeutic candidates. This approach en-
ables the bypassing of certain steps of the development
process, which reduces the cost of research and develop-
ment (R&D) and shortens the “bench to market” period
without compromising safety [15, 16]. In this framework
and following the same open-access model as the Mal-
aria Box [17] and the Pathogen Box [18], Medicines for
Malaria Venture (MMV) selected and compiled a library
of 400 compounds. The so-called Stasis Box includes
drugs that were stopped at an advanced stage in their
clinical development. The reasons for this termination
were different for each drug and ranged from lack of ef-
ficacy to bankruptcy of the developing company. The
availability, the “druglikeness” and the affordability of
these molecules were the main criteria used by MMV to
build this library. Screening the Stasis Box already identi-
fied hits against Haemonchus contortus and Madurella
mycetomatis [19, 20]. It represents therefore a promising
and unique repertoire of advanced drugs to test on other
organisms particularly those being responsible for
neglected tropical or rare diseases. In this study, the activity
of the Stasis Box was screened on Schistosoma mansoni.
These compounds were first tested in vitro on newly trans-
formed schistosomula (NTS). Hits progressed into testing
on adult worms and in vitro toxicity assays. In vivo studies
were performed with selected lead molecules.
Methods
Media and compounds
The Stasis Box compounds were compiled for MMV by
Evotec (Hamburg, Germany) in 96-wells plates as 10 mM
solutions and dissolved in 10 μl pure DMSO. The plates
were stored at -80 °C until use. Stock solutions (1 mM) in
M199 medium were prepared for the in vitro assays. For
IC50 determination on adult worms, cytotoxicity assays
and in vivo studies, MMV690732 and MMV690787
were purchased from Adooq Bioscience (Irvine, USA),
MMV690596, MMV690599 and MMV690646 were pur-
chased from Bio-Techne (Minneapolis, USA), MMV690466
and MMV690765 were purchased from SanBio BV/Cayman
(Uden, The Netherlands), MMV690684 was purchased
from Selleck Chemicals (Houston, USA), MMV690534
and MMV001539 were purchased from Sigma-Aldrich
(Buchs, Switzerland). For NTS transformation and main-
tenance of the parasites, Hank Balanced Salt Solution 1X
(HBSS), M199 medium and RPMI 1640 were purchased
from Gibco (Waltham MA, USA). Penicillin/Streptomycin
10’000 U/ml and inactivated foetal calf serum (iFCS) were
purchased from Bioconcept AG (Allschwil, Switzerland).
For cytotoxicity assays, rat skeletal myoblast L6 cells were
grown in RPMI supplemented with FCS and L-glutamin
(Sigma-Aldrich). Podophyllotoxin (PTT) was purchased
from Sigma-Aldrich and stock solutions (5 μg/ml) were
prepared in L6 cells medium.
Schistosoma mansoni adult worms and schistosomula
The S. mansoni (Liberian strain) life-cycle, is maintained
in-house at the Swiss Tropical and Public Health Institute
(Swiss TPH), as described before [21]. Biomphalaria
glabrata were infected with 6 to 8 S. mansoni miracidia.
They were kept in pond water under natural light,
temperature and humidity conditions until the infectious
stage, the cercariae, started to shed. The cercariae were
mechanically transformed to schistosomula, the NTS,
using a procedure adapted from Milligan & Jolly [22].
NTS were incubated (37 °C, 5% CO2) until use for 12 to
maximum 24 h in M199 medium supplemented with FCS
and antibiotics. Adult S. mansoni of both sexes were col-
lected by dissecting the intestinal veins of mice euthanized 7
weeks post-infection. All the adult worms recovered were in-
cubated for maximum one week until use in RPMI medium
supplemented with FCS and penicillin-streptomycin.
In vitro assays
For in vitro screening on NTS, the parasite suspension
was adjusted to 50 NTS/100 μl in supplemented M199
medium and added to the drug dilutions in 96-wells
plates (Eppendorf AG, Hamburg, Germany). NTS were
initially exposed to a drug concentration of 10 μM (0.1%
DMSO). Each drug was tested in duplicate.
Hit compounds identified on NTS progressed into
testing on adult worms. Females, males and pairs (3 to 5
worms per well) were exposed to the drug dilution in sup-
plemented RPMI medium. The assays were performed in
duplicate in 24-wells plates (Eppendorf AG, Hamburg,
Germany). IC50 values were determined for compounds
that demonstrated a high activity against NTS and adults
(effect ≥ 75% at 10 μM after 72 h). Each assay on NTS was
performed in triplicate with serial drug dilutions (1:2,
range: 10–0.16 μM) and repeated once. Similarly, the IC50
values on adult worms were determined after incubating the
worms for 72 h in serial drug dilutions (1:3, range: 33.3–1.23
μM). Each IC50 assay was repeated once. These assays were
repeated for the lead compounds in presence of albumin
(BSA) at the human physiological concentration of 45 g/l
(AlbuMAX II, Gibco). For all in vitro assays (NTS and
adults), negative controls containing the highest concentra-
tion of DMSO were included. Worms incubated with prazi-
quantel served as positive controls. The parasites were
evaluated under an inverted optical microscope over 3 days
after drug exposure. Their movement and morphology
were assessed and scored as described previously [23, 24].
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Cytotoxicity assays
Rat skeletal myoblast L6 cells (2 × 104 cells/ml) were
exposed to serial dilutions of the 11 lead compounds
(1:3, range: 0.37–90 μM). Podophyllotoxin (PPT, 1:3,
range: 2 × 10-4 –0.05 μg/ml) was used as a positive
control. After a 72-hour incubation, resazurin dye (Alamar
Blue) was added to the plates. Fluorescence and the
cytotoxic concentration (CC50) were measured at 530 nm
excitation and 590 nm emission wavelength using a
SpectraMax M2 (Molecular Device, Sunnyvale CA, USA;
Softmax version 5.4.6). Each drug was tested in duplicate
and each assay was repeated once.
In vivo studies
Three weeks old NMRI female mice were used (Charles
Rivers, Germany) for in vivo drug efficacy studies. The
animals were kept in groups of ten with constant access
to food and water. After one week of habituation, mice
were sub-cutaneously injected a suspension containing
100 S. mansoni cercariae in phosphate-buffered saline
(PBS). The drugs (200 mg/kg single dose) were ad-
ministered seven weeks post-infection by oral gavage
to groups of 4 mice. They were dissolved in tap water
with Tween80/ethanol (10%, 70:30). Untreated mice
(n = 10) served as control and were dissected 7 weeks
post-infection. Treated mice (n = 40) were euthanized with
CO2 and dissected between 16 to 18 days post-drug ad-
ministration. The worms were then collected, sexed and
counted.
Statistics
For in vitro assays, the average viability scores between
replicates (or individual adult worms) were normalised
to the controls and converted into percentage activity
(or effect). Drug IC50 values (for NTS or adult worms)
were calculated by computing different dose-effect
values using CompuSyn2 software (ComboSyn Inc.,
2007). The linear correlation coefficient (r) reflects the
experimental fit. In this study, r-values > 0.70 were con-
sidered acceptable. The mean IC50 were considered for
analysis only if the values obtained in each replicate did
not differ more than 5.5-fold. The selectivity index (SI)
of each drug was calculated by dividing the CC50 mea-
sured on the L6 cells by the IC50 measured on the para-
sites. For in vivo studies, as previously described [25],
the worm burden reduction [%] was determined by com-
paring the worm burden of treated and untreated mice.
For statistical significance a Kruskal-Wallis test was
employed (R version 3.2.2).
Results
In vitro studies
Following incubation for 72 hours, 37 of the 400 drug-
like compounds screened were active on NTS at 10 μM
(effect ≥ 50%), including 16 that were lethal (effect = 100%)
and 10 that were highly active (effect ≥ 75%). Seven of
these were fast-acting as they demonstrated a high activity
on NTS already after 24 hours (Table 1). The compounds
with a moderate effect (< 75%) after 72 h were not investi-
gated further, while the 26 most active ones and
MMV690466 - that showed a high effect at the 48 hour
time point - proceeded to adult testing (Fig. 1). Sixteen
compounds showed only a moderate (effect < 75%) activity
against adult worms. On the other hand, 7 compounds dis-
played a high activity against adult worms and 4 were even
lethal (Table 1). Of these, 5 compounds were already highly
active against the adult worms after one day incubation
period at 10 μM. These 11 compounds were selected as in
vitro leads. Compound characteristics and structures are
presented in Table 2 and Fig. 2. IC50 values calculated 72 h
post-incubation ranged from 2 to 7.5 μM on adult worms
and 0.5 to 7.2 μM on NTS. In the presence of albumin, a
strong decrease in activity of the lead compounds on adult
worms was observed (Table 3). The highest activities were
observed for MMV003452 and MMV690684 revealing
IC50 values of 7.5 and 7.7 μM, respectively, denoting
a 2-fold increase compared to the values observed with-
out albumin supplementation. The mean IC50 values of
MMV690596, MMV690599 and MMV690787 were be-
tween 10 and 16 μM in the presence of albumin (indicating
a 5.4-, 6.1- and 4.3-fold increase, respectively compared to
the IC50 values without albumin). The remaining 6 com-
pounds showed no activity in the presence of albumin
(Table 3).
The lead molecules were rather cytotoxic, except for
MMV690534 that showed, on both mammalian cell lines
acceptable parasite-selectivity (SI > 1). When measured
on L6 rat myoblast cells MMV690596, MMV003452,
MMV690599 and MMV690684 were slightly above the
selectivity cut-off while MMV690732 and MMV690466 were
slightly below. Although MMV690466 and MMV001539
were not selective towards the worms when measured
with L6 cells, the SI was > 1 when measured on MRC5
cells (Table 3).
Table 1 Number of hits identified after the initial screen of the
Stasis Box at 10 μM
Evaluation time point
24 h 48 h 72 h
NTS hits (effect ≥ 50%) 11 23 37
NTS (effect > 75%) 4 9 10
NTS (lethal) 3 9 16
Adult hits (effect ≥ 50%) 11 9 16
Adult (effect > 75%) 5 4 7
Adult (lethal) 0 2 4
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In vivo activity
All the compounds tested (n = 10) failed to significantly
reduce the worm burden in vivo. Eight compounds
had no effect on the worm burden in infected mice
(worm burden reduction < 36%). Although MMV690534
showed a worm burden reduction slightly above 50%,
it was not statistically significant (P > 0.05). The mice
treated with MMV690646 (Ispinesib) died prematurely
and therefore, were not included in the analysis
(Table 4).
Discussion
The Stasis Box includes late leads that were abandoned,
mainly due to a lack of efficacy against their primary tar-
get disease. This library represents therefore a unique
repertoire of molecules to test on different organism in-
cluding S. mansoni as the compounds already underwent
advanced clinical test phases, which should guarantee
satisfactory safety and pharmacological properties.
After screening these drugs in vitro on both larval and
adult stages of the parasite, 11 lead molecules revealed
Fig. 1 Workflow of the Stasis Box screening on S. mansoni worms. a 26 highly effective hits tested on adults and MMV690466 that showed high
activity at 48 h. b MMV001539 was not available in quantity required for in vivo studies
Table 2 Stasis Box lead molecules
MMV ID CHEMBL ID Name(s) Indication Mechanism of action Target
MMV690732 CHEMBL3545403 XL-139;
BMS-833923
Cancer Smoothened homolog
antagonist
Smoothened homolog
MMV690596 CHEMBL1836102 CGP-71683 Obesity, eating disorder Neuropeptide receptor
antagonist
na
MMV003452 CHEMBL15928 GR-127935 Depression 5-HT 1B/1D receptor
antagonist
5-HT 1B and 5-HT 1D
receptors
MMV690599 CHEMBL88272 RS-17053 Prostate hyperplasia Alpha 1 adrenoreceptor
antagonist
na
MMV690466 CHEMBL59030 GW-3965 Inflammation, melanoma Agonist of LXR receptor na
MMV690787 CHEMBL513909 BI-2536 Cancer Serine/threonine-protein
kinase PLK1 inhibitor
Serine/threonine-protein
kinase PLK1
MMV690684 CHEMBL91867 CL-387785 Cancer Epidermal growth factor
receptor (EGFR) receptor
antagonist + Tyrosine
Kinase (TK) inhibitor
na
MMV690646 CHEMBL2111096 CK0238273;
SB-715992-S;
Ispinesib
Cancer Kinesin inhibitor KIF11
MMV690765 CHEMBL607707 EKB-569;
Pelitinib
Cancer EGFR erbB1 inhibitor EGFR erbB1
MMV690534 CHEMBL238125 SD-208 Cancer, chronic pulmonary
obstruction
TGFb TK inhibitor +
receptor antagonist
na
MMV001539 CHEMBL16687 CGS-15943 Ischemia, stroke Adenosine A2 receptor
antagonist
na
Abbreviation: na not available
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strong antischistosomal activity. With the exception of
MMV690534 (SD-208) and MMV001539 (CGS-15943),
the IC50 of the compounds measured on adult worms
were already below 10 μM after 24 h, hence the com-
pounds were fast acting (Table 3). Speed of action is an
important parameter for defining antischistosomal
activity as worms will be exposed only very shortly to high
mesenteric vein concentrations of the unmetabolised drug
[26]. Speed of action was also already taken into account
for drug selection and progression in our previous
Fig. 2 Chemical structures of the Stasis Box lead molecules. Source: ChEMBL
Table 3 IC50 values on NTS and adult S. mansoni, toxicity on L6 and MRC5-cells and selectivity of the 11 Stasis Box lead molecules.
Cytotoxic concentration (CC50) and selectivity index (SI) are compared to the mean IC50 values measured on NTS and adult S. mansoni in
standard and albumin-enriched medium (45 g/l) over 72 h with 11 Stasis Box lead compounds
Compound
MMV ID
NTS IC50 (μM)
a Adult IC50 (μM)
a Adult IC50 (μM) with albumin
a L6 cells MRC5 cellsd
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h CC50 (μM) SI CC50 (μM) SI
MMV690732 29.5 6.3 3.5 4.9 2.9 2.5 62.8 181.0 54.1 2.3 0.9 1.9 0.7
MMV690596 1.1 1.3 0.6 1.0 2.1 2.0 27.5 14.4 11.0 3.5 1.7 1.9 0.9
MMV003452 4.4 2.2 1.2 1.7 3.0 2.7 22.6 12.0 7.5 3.7 1.4 1.9 0.7
MMV690599 10.5 3.5 1.5 2.5 3.3 2.6 23.6 19.1 15.9 3.4 1.3 2 0.8
MMV690466 14.6 3.8 2.1 2.9 2.3 2.0 18.1b 89.7 47.6 1.6 0.8 8.4 4.3
MMV690787 38.4b 8.1 6.3 7.9 7.2 3.1 39.5 14.4 13.3 na na 0.1 0
MMV690684 4.0c 3.1c 0.7 4.9 4.7 3.7 76.8 14.4b 7.7 7.0 1.9 7 1.9
MMV690646 3.0c 1.1 0.9 3.7 2.2 2.2 32.0 121.8 33.6 na na 0.2 0.1
MMV690765 914.4b > 1c 0.5b 4.2 3.4 2.9 651.7 225.9b 123.5b 11.8 4.1 0.7 0.3
MMV690534 11.8 14.3c 7.2c 17.4 19.3 7.5 na na na 74.5 15.0 12.4 2.5
MMV001539 12.7 11.0c 1.7 28.2 12.3 7.0 nd nd nd 2.9 0.4 16 2.1
Abbreviations: na not applicable. nd not done
ar-values ranged between 0.7 and 1.0
bThese values are based on one replicate only because of an r-value < 0.70 was obtained for the second replicate
cThe IC50 values obtained in each of the two replicate differed more than 5.5-fold
dThe CC50 values on MRC5 cells were provided by MMV
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screenings of an FDA library of approved drugs [25] and
of a set of oncology drugs [27]. Although the IC50 values
measured on NTS after 24 h were very different, they all
ranged under the 10 μM cut-off 72 h post-incubation.
The high in vitro activity changed in presence of albu-
min at the human plasma concentration of 45 g/l. The
efficacy of each molecule dropped considerably, notably
for MMV690732 (XL-139), MMV690466 (GW-3965)
and MMV690646 (Ispinesib) that showed high IC50
values ranging from 30 to 55 μM 72 h post-drug ex-
posure in the presence of this protein (Table 3). This
finding suggests a strong drug-binding effect of albu-
min. This finding is consistent with the incapacity of
all the lead molecules tested in vivo to significantly
reduce the worm burden in infected mice. Hence, the
lack of efficacy in vivo might have been caused by a strong
drug-binding effect of the host plasma proteins reducing
therefore the amount of free drug available to kill the
parasite. However, other factors that affect pharmacoki-
netic processes such as drug metabolism might obviously
also play a role.
In order to avoid losing advanced drug leads as poten-
tial novel antischistosomal drugs, the hit to lead selec-
tion criteria in the present work was less strict than in
our previous screenings [25, 27]. For this reason and be-
cause the Stasis Box drugs were assumed to have an
acceptable safety and pharmacokinetic profile (at least
for the relevant therapeutic indication), all compounds
moved into in vivo testing despite a higher IC50 in the
presence of albumin. However, plasma protein binding
should be considered among other factors (as clearance,
safety, exposure) in the screening cascades, as suggested
by Gelmedin et al. [28].
Oncology is a privileged source of drugs to repurpose
against schistosomiasis and other NTDs, particularly be-
cause of their potency to interfere with conserved signal-
ling pathways that are also involved either in the
metabolism or the reproduction of the parasite [11, 15, 29].
For instance, the antischistosomal activity of different pro-
tein kinase inhibitors (PTK) has been described previously
[28, 30–33]. Also many of the hits identified in our study
were developed to target intracellular neoplastic pathways
(Table 2). However, one of the disadvantages working with
anticancer drugs is obviously toxicity. Although the Stasis
Box compounds were selected for their “druglikeness”, the
majority of the lead molecules identified were moderately
toxic as demonstrated by our cytotoxicity tests, the data
provided by MMV, and the death of the mice treated with
MMV690646 (Ispinesib). Nonetheless, the identified oncol-
ogy late leads could serve as starting point for future stud-
ies. For example, structure-activity relationship (SAR)
studies on these pharmacophores should be conducted to
identify less toxic hits.
Our study identified different lead candidates in vitro,
which likely act on different targets in S. mansoni. For ex-
ample, we confirmed the in vitro activity of the Polo-like
kinase (Plk) competitive inhibitor BI-2536 (MMV690787)
on S. mansoni [28, 32, 34] targeting SmPlk1 and hence
resulting in reproductive impairment of both sexes.
MMV690534 (SD-208) might have impaired the repro-
ductive function of the parasite by interfering with the
TGF-beta mediated intracellular signalling pathway not-
ably involved in egg production [28, 35, 36]. Aside from
reproduction, other functions in S. mansoni may have been
negatively impacted. For example, epidermal growth factor
receptors (EGFR) might have been targeted by antagonists
such as MMV690765 (Pelitinib), while MMV001539 (CGS-
15943) might have interacted with purinergic receptors.
These few examples illustrate the variety of potential targets
in S. mansoni, notably for kinase inhibitors. In this study, in
vitro tests were assessing parasite phenotype (e.g. motility,
shape, or colour) after drug exposure. No parameters
related to the reproductive function (e.g. egg count) were
recorded, which is a limitation of our study given the im-
portance of protein kinases in reproduction.
Considering the good activity in vitro of some of these
compounds, it would be worth testing analogues and ini-
tiate SAR studies. As the information openly available
on these compounds was scarce, manufacturers should
be encouraged to provide more information in the pub-
lic domains. Functional studies are also essential to bet-
ter characterize potential drug targets and design more
effective and selective drugs.
Conclusions
Despite the fact that no drugs with clear in vivo anti-
schistosomal activity emerged from the Stasis Box
Table 4 In vivo efficacy of the lead molecules from the Stasis
Box. Effect on worm burden of a single 200 mg/kg oral dose of
nine lead molecules identified after screening the Stasis Box in
vitro administered to mice harbouring a 49-day-old adult
S. mansoni infection
Compound Mice testedn Mean worm burden ± SD WBR (%)
MMV690732 41 47.5 ± 24.3 0
MMV690599 31 44.7 ± 29.6 3.2
MMV690787 41 48.3 ± 21.6 0
MMV003452 41 40.5 ± 17.2 12.2
MMV690596 41 52.0 ± 22.7 0
MMV690684 41 41.5 ± 16.5 10.0
MMV690765 31 84.0 ± 56.4 0
MMV690466 42 10.3 ± 6.9 35.9
MMV690534 42 7.8 ± 7.5 51.6
Control1 8 46.1 ± 21.9
Control2 2 16.0 ± 19.8
n Indicates the mice control batch. One mouse died prematurely because of
toxic effects of MMV690646 (Ispinesib) and therefore data is not shown
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screening on S. mansoni, different molecules were iden-
tified with promising in vitro activity. Together with a
better understanding of their potential drug targets, SAR
studies could be conducted, particularly taking into ac-
count protein binding and in vivo pharmacokinetics.
Our findings confirmed that open access libraries such
as the Stasis Box are powerful and yet essential tools for
drug discovery on NTDs.
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